Cambridge Heart to Launch ''MASTER'' Study Identifying Patients in Greatest Need of Implantable Cardiac Defibrillators.

Business Editors/Health/Medical Writers

BEDFORD, Mass.--(BUSINESS WIRE)--Dec. 10, 2002

Unique Non-Invasive Technology Will Stratify Risk of Sudden

Cardiac Arrest among 1,800 Post-Heart-Attack Patients

at 50 Leading Medical Centers Worldwide

Cambridge Heart, Inc. (NASDAQ:CAMH), developer of the only FDA-cleared non-invasive test for assessing an individual's risk of Sudden Cardiac Death (SCD), will launch, early next year, a new clinical study to identify heart-attack patients who will benefit most from implantable cardioverter defibrillators (ICDs).

The Company's innovative technology, Microvolt T-Wave Alternans (MTWA), detects extremely subtle electronic fluctuations in a person's heartbeat that are not visible on electrocardiograms. These tiny fluctuations are strong predictors of Sudden Cardiac Death, which results from an electrical, rather than vascular, malfunction of the heart. More than 400,000 Americans die each year from SCD. The risk of SCD increases very significantly in patients who have already suffered a damaging heart attack.

The MASTER Study (Microvolt T-Wave AlternanS Testing for Risk Stratification of Post MI Patients) will target post-myocardial infarction (MI) patients whose hearts have been damaged by previous heart attacks. About one in every ten heart-attack patients who are left with poor heart pumping function will die of heart-rhythm abnormalities within two years, according to the American College of Cardiology. Results of the recent MADIT II clinical trial, published in the New England Journal of Medicine, showed that implantable defibrillators improve survival in this group by 31 percent. If members of this high-risk group can be stratified more precisely through a non-invasive test conducted in a clinic or doctor's office, ICD implantations can be more cost-effective and reduce mortality rates still further for this population.

The Study, to be conducted in conjunction with a leading medical technology company, will take place at up to 50 leading medical centers around the world. 600 patients meeting MADIT II criteria (post heart attack and 30% or less ejection fraction) will be enrolled in the Study. Another 1,200 patients, with slightly better pumping function (ejection fraction 30% to 40%) will be evaluated in a related registry. Results of the study are expected to be available in late 2005.

"Many of the physicians we speak to are looking for a non-invasive way to assess the MADIT II population so they can make the best possible decisions about life-saving ICD therapy," said David Chazanovitz, President and CEO of Cambridge Heart, Inc. "The MASTER Study will help us evaluate this specific population and more precisely identify those at greatest risk of sudden cardiac arrest."

About Cambridge Heart's Microvolt T-Wave Alternans Test

The only FDA-cleared, non-invasive test for assessing an individual's risk of Sudden Cardiac Death, Cambridge Heart's MTWA Test has received a CPT code (93025) for billing and reimbursement purposes. The MTWA Test is currently in use at many leading hospitals and physician practices across the country. It can be performed as a stand alone test or in conjunction with a variety tests which elevate the heart rate. In numerous clinical studies published in the medical literature, Microvolt T-Wave Alternans has demonstrated that its predictive ability is approximately equal to the invasive electrophysiology (EP) study in predicting which individuals will experience a cardiac event and more powerful that the EP study in predicting which patients are not at risk of a cardiac event.

About Cambridge Heart, Inc.

Cambridge Heart is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. Using innovative technologies developed at the Massachusetts Institute of Technology (MIT) and Harvard Medical School, the Company is addressing such key problems in cardiac diagnosis as the identification of those at risk of sudden cardiac arrest. Founded in 1990, the Company is based in Bedford, Mass. and is traded on the NASDAQ under the symbol CAMH. For more information, please visit www.cambridgeheart.com

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: failure to achieve broad market acceptance of our products, adverse results in future clinical studies of our technology, failure to obtain or maintain patent protection for our technology, failure to obtain or maintain adequate levels of third-party reimbursement for use of our products and other factors discussed in our most recent quarterly report filed with the SEC. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this press release. The Company specifically disclaims any obligation to update these forward-looking statements.